• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

DLBCL

home / clinical-spotlight / dlbcl
Matthew Lunning, DO, headshot
September 11, 2023
Dr Matthew Lunning: Chaos of DLBCL Treatments Needs Organization
There are multiple treatment options becoming available for diffuse large B-cell lymphoma, but more work needs to be done to understand their efficacy and in what lines of therapy they should be used.
Christopher D-Andrea, PA-C headshot
August 18, 2023
Christopher D’Andrea: It Takes a Village to Treat Patients With CAR T-Cell Therapy
Even patients with diffuse large B-cell lymphoma who are eligible for chimeric antigen receptor (CAR) T-cell therapy face multiple barriers to care and need assistance.
Kami Maddocks, MD
August 8, 2023
Dr Kami Maddocks: Advances in DLBCL Treatment Despite Challenges in Research
Although B-cell lymphomas can be challenging to study, there have been great advances in treatments in the second-line and later, explained Kami Maddocks, MD, professor of Clinical Internal Medicine, the Ohio State James Comprehensive Cancer Center.
Elizabeth Brem, MD
July 12, 2023
Dr Elizabeth Brem Discusses the Evolving Landscape of DLBCL Treatments
Chimeric antigen receptor T-cell therapies are already moving into earlier lines of therapy for patients with diffuse large B-cell lymphoma (DLBCL), and now people are looking at when to use bispecific antibodies.
Christopher Flowers, MD
June 28, 2023
Dr Christopher Flowers Discusses Second-Line Therapies for B-Cell Lymphomas
There are various immunotherapies being used in the second ling for patients with lymphomas, some of which have curative potential, explained Christopher Flowers, MD, MS, of the University of Texas MD Anderson Cancer Center.
Dr Tycel Phillips
June 5, 2023
Dr Tycel Phillips on Progress in B-Cell Lymphoma Treatment
In this interview, Tycel Phillips, MD, associate professor of medicine, Division of Lymphoma and Bone Marrow Transplantation, City of Hope, Duarte, California, discusses the advancements that are shaping the future of B-cell lymphoma treatment, as well as access barriers.
Fakhri Reviews Considerations for Second-Line Therapy in DLBCL
August 16, 2022
Fakhri Reviews Considerations for Second-Line Therapy in DLBCL
Nearly 5 years after approval of the first CAR T-cell therapy, treatment is moving into second line, and patients have more options than ever for diffuse large B-cell lymphoma. How do physicians choose? Bita Fakhri, MD, MPH, hematologist-oncologist at the University of California San Francisco, discusses the process.
Paolo Caimi, MD
August 8, 2022
Dr Paolo Caimi Highlights the Need for Access and Better Treatments in DLBCL
Facilitating access to treatments for diffuse large B-cell lymphoma (DLBCL) remains a top issue.
With Successor to R-CHOP on Horizon, Habermann Says DLBCL Treatment Choices Create “Complicated World”
July 17, 2022
With Successor to R-CHOP on Horizon, Habermann Says DLBCL Treatment Choices Create “Complicated World”
Zelenetz Discusses How to Evaluate Responses to Therapy in DLBCL
June 22, 2022
Zelenetz Discusses How to Evaluate Responses to Therapy in DLBCL
Andrew Zelenetz, MD, PhD, medical oncologist at Memorial Sloan Kettering Cancer Center, is the current chair of the Non-Hodgkin Lymphoma Guidelines panel of the National Comprehensive Cancer Network (NCCN).
Moffitt’s Dr Julio Chavez Discusses New Treatment, Sequencing Options in DLBCL
May 22, 2022
Moffitt’s Dr Julio Chavez Discusses New Treatment, Sequencing Options in DLBCL
Julio Chavez, MD, MS, of Moffitt Cancer Center, spoke with The American Journal of Managed Care® (AJMC®) about how new approvals will alter decision making in the treatment of diffuse large B-cell lymphoma (DLBCL).
Dr Kami J. Maddocks Highlights Progress of Last 5 Years in DLBCL
May 2, 2022
Dr Kami J. Maddocks Highlights Progress of Last 5 Years in DLBCL
Kami J. Maddocks, MD, professor of clinical internal medicine in the Division of Hematology at The Ohio State University Wexner Medical Center, spoke with The American Journal of Managed Care® (AJMC®) about treatment approaches for diffuse large B-cell lymphoma (DLBCL).
© 2024 MJH Life Sciences
AJMC®
All rights reserved.